Clinical Trial

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

Name: Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC — clinical trial record (NCT04522544)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: IMMUWIN

Active, Not Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

A Phase II study of immunotherapy with Durvalumab (MEDI4736) and Tremelimumab in combination with Y-90 SIRT for intermediate stage HCC

Protocol Amendment History 1 change

critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-24

Trial Details

NCT Number	NCT04522544
Lead Sponsor	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Collaborators: AstraZeneca, Hannover Medical School
Conditions	Hepatocellular Carcinoma Non-resectable, HCC
Enrollment	55 participants
Start Date	2020-12-15
Primary Completion	2027-07-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-23